Overall survival of patients with
afatinib
erlotinib
gefitinib
lung cancer
real-world data
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
06
2018
accepted:
13
11
2018
entrez:
13
12
2021
pubmed:
22
1
2019
medline:
22
1
2019
Statut:
epublish
Résumé
The aim of the study was to estimate the overall survival of patients with Real-world patients who received afatinib, erlotinib or gefitinib between 1 July 2012 and 30 October 2017 were analysed in five subgroups. Among 267 patients treated with afatinib financed as the first line of treatment, 76 (28.46%) deaths occurred. Median observation time was 12.8 months (95% CI: 11.2-13.9). Median OS was 22.8 months (95% CI: 19.2-27.1). Among 83 patients who received erlotinib financed exclusively as the second line of treatment the number of deaths was 74 (89.16%). Median observation time was 64.3 months (95% CI: 60.4-64.6). Median OS was 16 months (95% CI: 13.2-22.9). Among 622 patients who received erlotinib financed both as first and second line treatment, there were 400 (64.3%) deaths. Median observation time was 33.3 months (95% CI: 31.2-37.6). Median OS was 17.8 months (95% CI: 16.4-19.7). Among 137 patients who received gefitinib financed only as the first line of treatment, there were 128 (93.4%) deaths. Median observation time was 58.3 months (95% CI: 49.4-62.5). Median OS was 16 months (95% CI: 13.8-19.7). Among 348 patients who received gefitinib financed both as the first and second line of treatment the number of deaths was 208 (59.8%). Median observation time was 23.7 months (95% CI: 20.7-28.7). Median OS was 15.5 months (95% CI: 12.9-17.5). Our real-world data regarding OS confirm the benefits found in clinical trials from the use of afatinib, erlotinib or gefitinib. However, the lower overall survival rate of Polish patients compared to similar studies from other research centres suggests the need for deeper investigation of this issue.
Identifiants
pubmed: 34900041
doi: 10.5114/aoms.2018.80362
pii: 99749
pmc: PMC8641509
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1618-1627Informations de copyright
Copyright: © 2019 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Int J Cancer. 2017 Jun 15;140(12):2805-2819
pubmed: 28295308
Arch Med Sci. 2015 Oct 12;11(5):1033-43
pubmed: 26528348
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Ann Oncol. 2015 Sep;26(9):1883-1889
pubmed: 26105600
Anticancer Res. 2018 Jan;38(1):393-400
pubmed: 29277800
Ann Oncol. 2017 Feb 1;28(2):270-277
pubmed: 28426106
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Ann Oncol. 2015 Sep;26(9):1877-1883
pubmed: 26141208
Ann Oncol. 2013 Jan;24(1):54-9
pubmed: 22967997
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Eur Respir Rev. 2014 Mar 1;23(131):92-105
pubmed: 24591666
Clin Cancer Res. 2014 Apr 1;20(7):2001-10
pubmed: 24493829
Oncol Res. 2018 Aug 23;26(7):1031-1036
pubmed: 29321093
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168